Dominique Berton-Rigaud

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 599 citations · Full text

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Journal of Clinical Oncology · 2017 · 504 citations

Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography

Caroline Rousseau, Anne Devillers, Christine Sagan et al. · Journal of Clinical Oncology · 2006 · 310 citations · Full text

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028

Andréa Varga, Sarina A. Piha‐Paul, Patrick A. Ott et al. · Gynecologic Oncology · 2018 · 269 citations

Advanced Ovarian Cancer, Medicine, Immunology +9

Safety and dose modification for patients receiving niraparib

Jonathan S. Berek, Ursula A. Matulonis, Ulla Peen et al. · Annals of Oncology · 2018 · 183 citations